The cascade from obesity to diabetes may have found a critical molecular chokepoint. Fat tissue scarring—a hallmark of metabolic dysfunction—appears controllable through targeting a specific protein that orchestrates the inflammatory response in adipose progenitor cells.
Single-cell sequencing revealed that fibulin-7 (FBLN7) becomes significantly elevated in stem cells within visceral fat of obese individuals. When researchers knocked out FBLN7 specifically in these adipose stem and precursor cells, mice fed high-calorie diets showed dramatically reduced fat tissue inflammation and scarring compared to controls. The protective effect extended beyond local tissue health to systemic metabolic improvements.
The molecular mechanism centers on FBLN7's interaction with thrombospondin-1, where FBLN7 stabilizes this partner protein through calcium-binding domains. This partnership amplifies TGF-β signaling—a master regulator of tissue scarring—by converting inactive TGF-β into its bioactive form. The resulting cascade drives the transformation of healthy fat tissue into fibrous, metabolically dysfunctional tissue characteristic of obesity-related insulin resistance.
This research fills a significant gap in understanding how fat tissue transitions from healthy expansion to pathological dysfunction. Most obesity interventions target caloric intake or energy expenditure, but this work suggests therapeutic potential in preserving adipose tissue quality during weight gain. The development of an anti-FBLN7 neutralizing antibody that reversed diet-induced metabolic damage in animal models represents a novel therapeutic approach. However, the complexity of TGF-β signaling across multiple organ systems demands careful evaluation of systemic effects before clinical translation. The findings suggest that maintaining adipose tissue health, rather than simply preventing weight gain, could offer a complementary strategy for metabolic disease prevention.